Research graph
References from Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care. Local targets link to admitted publications; unresolved targets remain external evidence.
Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer
10.1016/j.eururo.2018.07.027 · 2019 · External reference
10.1200/jco.2022.40.6_suppl.tps285
10.1200/jco.2022.40.6_suppl.tps285 · 2022 · External reference
Perioperative apalutamide in high-risk localized prostate cancer
10.1056/nejmoa2603878 · 2026 · External reference
Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy
10.1016/j.urolonc.2019.12.014 · 2020 · External reference
Heterogeneity in definitions of high-risk prostate cancer and varying impact on mortality rates after radical prostatectomy
10.1016/j.euo.2018.02.004 · 2018 · External reference
NCCN Guidelines® insights: prostate Cancer, version 3.2024
10.6004/jnccn.2024.0019 · 2024 · External reference
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era
10.1002/cncr.10657 · 2002 · External reference
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
10.1001/jama.280.11.969 · 1998 · External reference
STROBE reporting guidelines for observational studies
10.1001/jamasurg.2021.0528 · 2021 · External reference
The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival
10.1016/j.juro.2008.09.027 · 2009 · External reference
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods
10.1016/j.juro.2007.03.105 · 2007 · External reference
LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
10.1016/j.annonc.2025.09.102 · 2025 · External reference
Artificial intelligence predictive model for hormone therapy use in prostate cancer
10.1056/evidoa2300023 · 2023 · External reference
Performance of a prostate-specific membrane antigen positron emission tomography/computed tomography–derived risk-stratification tool for high-risk and very high-risk prostate cancer
10.1001/jamanetworkopen.2021.38550 · 2021 · External reference
